UNSPSC 51391501: Imoxiterol

This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UR4924C6G2. European Medicines Agency schedules Imoxiterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08157MIG. Imoxiterol generally arises in the molecular formula C20H25N3O3.

UNSPSC 51391501 Imoxiterol is a Commodity code that does not align with the actual procurement activity in the source data. The most recent state-local opportunity tagged under this code is Seminole County, Florida's IFB 60459723LAS, which solicits naloxone and drug deactivation systems—opioid-response medical supplies and harm-reduction equipment—rather than imoxiterol, a distinct pharmaceutical compound. The source shows no additional opportunities under this code and no clear pattern of state and local governments procuring imoxiterol as a standalone product line.

The single sourced opportunity represents county-level public health procurement: Seminole County released an IFB on June 30, 2026 (with a response deadline of July 26, 2023, per the source record), seeking 1,900 naloxone units and 800 safe drug deactivation systems annually for quarterly delivery to the county's Community Health Building in Sanford, Florida. The procurement requires vendors to meet E-Verify compliance, drug-free workplace certification, and insurance coverage thresholds, with a two-year initial term and one-year renewal option. The mismatch between the assigned UNSPSC code (imoxiterol) and the work actually being purchased (naloxone and drug deactivation systems) suggests either a coding error in the state-local system or that this code designation does not reflect current procurement patterns. No additional geographic spread or repeat-buyer activity is evident in the source.